elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
Hormonal therapy
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Hormonal therapy
RIS
0.000
(Research Intensity Score)
Papers
69
Top papers
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
2019 · 1574 citations
Metastatic Prostate Cancer—A Review of Current Treatment Options and Promising New Approaches
2023 · 134 citations
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
2022 · 122 citations
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review
2023 · 55 citations
Advances in Ultrasound-Targeted Microbubble Destruction (UTMD) for Breast Cancer Therapy
2025 · 15 citations
The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer
2025 · 13 citations
The hormonal nexus in PIK3CA-mutated meningiomas: implications for targeted therapy and clinical trial design
2025 · 9 citations
Evolving Systemic Therapy for Prostate Cancer: Pivotal Clinical Trials, Biomarker-Driven Combinations, and Practical Sequencing in the ARSI–PARP–Radioligand Era
2026 · 1 citations
The DUET-1 trial: Feasibility and toxicity outcomes and early oncological outcomes of 177 lutetium-PSMA radioligand therapy (RLT) alternated with 233 radium-dichloride in patients with metachronous oligorecurrent osseus hormone sensitive prostate cancer (mHSPC).
2026
Newest papers
Evolving Systemic Therapy for Prostate Cancer: Pivotal Clinical Trials, Biomarker-Driven Combinations, and Practical Sequencing in the ARSI–PARP–Radioligand Era
2026 · 1 citations
The DUET-1 trial: Feasibility and toxicity outcomes and early oncological outcomes of 177 lutetium-PSMA radioligand therapy (RLT) alternated with 233 radium-dichloride in patients with metachronous oligorecurrent osseus hormone sensitive prostate cancer (mHSPC).
2026
Top advances of the year: Radiopharmaceutical therapy for prostate cancer
2026
Treatment Strategies in Metastatic Castration-Resistant Prostate Cancer: A Narrative Review of Considerations in the Post-ARTA, Post-Docetaxel Setting
2026 · 1 citations
Exceptional Response to Short-course 177Lu-PSMA Radioligand Therapy in a Patient With Metastatic Hormone-sensitive Prostate Cancer
2026
Treatments on the Horizon for Men with Advanced Prostate Cancer
2026
Impact of lutetium Lu 177 vipivotide tetraxetan on prostate cancer outcomes by race.
2026
Real-world utilization and timing of initiation of bone-targeting agents (BTAs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223: Results from Princess Margaret Cancer Centre (PM).
2026
The 177Lu-PSMA-617 PRLT “Superresponders” Among Metastatic Castration-Resistant Prostate Carcinoma (mCRPC) with Extensive Disease: Case Series with Review of Literature on PSMA-Based Theranostics in the Therapeutic Armamentarium of mCRPC
2026
Browse all papers →
Hormonal therapy's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Hormonal therapy's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link